EP 3558380 A1 20191030 - PHARMACEUTICAL DOSAGE FORMS CONTAINING TASK-1 AND TASK-3 CHANNEL INHIBITORS, AND THE USE OF SAME IN BREATHING DISORDER THERAPY
Title (en)
PHARMACEUTICAL DOSAGE FORMS CONTAINING TASK-1 AND TASK-3 CHANNEL INHIBITORS, AND THE USE OF SAME IN BREATHING DISORDER THERAPY
Title (de)
PHARMAZEUTISCHE DARREICHUNGSFORMEN ENTHALTEND INHIBITOREN VON TASK-1 UND TASK-3 KANÄLEN UND DEREN VERWENDUNG FÜR DIE THERAPIE VON ATEMSTÖRUNGEN
Title (fr)
FORMES PHARMACEUTIQUES CONTENANT DES INHIBITEURS DES CANAUX TASK-1 ET TASK-3 ET LEUR UTILISATION POUR LE TRAITEMENT DE TROUBLES RESPIRATOIRES
Publication
Application
Priority
- EP 16205688 A 20161221
- EP 17157805 A 20170224
- EP 2017082542 W 20171213
Abstract (en)
[origin: WO2018114501A1] The invention relates to new pharmaceutical dosage forms containing potent and selective TASK-1 and/or TASK-3 channel inhibitors, and the use of same to treat and/or prevent breathing disorders including sleep-related breathing disorders such as obstructive and central sleep apnea and snoring.
IPC 8 full level
A61K 9/08 (2006.01); A61K 31/496 (2006.01); A61K 47/10 (2017.01)
CPC (source: EP KR US)
A61K 9/0043 (2013.01 - EP KR US); A61K 9/08 (2013.01 - EP KR); A61K 31/496 (2013.01 - EP KR US); A61K 47/02 (2013.01 - KR); A61K 47/10 (2013.01 - EP KR US); A61K 47/12 (2013.01 - KR); A61K 47/26 (2013.01 - KR); A61P 9/00 (2017.12 - EP); A61P 9/06 (2017.12 - EP); A61P 11/00 (2017.12 - EP KR); A61P 25/00 (2017.12 - EP); A61P 25/20 (2017.12 - EP); A61P 25/28 (2017.12 - EP); A61P 43/00 (2017.12 - EP); A61K 9/08 (2013.01 - US)
Citation (search report)
See references of WO 2018114501A1
Designated contracting state (EPC)
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
Designated extension state (EPC)
BA ME
DOCDB simple family (publication)
WO 2018114501 A1 20180628; AU 2017379245 A1 20190711; BR 112019012836 A2 20191217; CA 3047426 A1 20180628; CL 2019001726 A1 20191129; CN 110290809 A 20190927; CO 2019006642 A2 20190918; CR 20190299 A 20190904; CU 20190063 A7 20200204; DO P2019000172 A 20190715; EC SP19044577 A 20190630; EP 3558380 A1 20191030; IL 267503 A 20190829; JO P20190148 A1 20190618; JP 2020502215 A 20200123; KR 20190099245 A 20190826; MA 47074 A 20210414; MX 2019007619 A 20190906; PE 20191240 A1 20190916; PH 12019501458 A1 20200601; TW 201834653 A 20181001; US 2020093737 A1 20200326; UY 37541 A 20180731
DOCDB simple family (application)
EP 2017082542 W 20171213; AU 2017379245 A 20171213; BR 112019012836 A 20171213; CA 3047426 A 20171213; CL 2019001726 A 20190620; CN 201780086896 A 20171213; CO 2019006642 A 20190621; CR 20190299 A 20171213; CU 20190063 A 20171213; DO 2019000172 A 20190619; EC DI201944577 A 20190621; EP 17822216 A 20171213; IL 26750319 A 20190619; JO P20190148 A 20170616; JP 2019533535 A 20171213; KR 20197020701 A 20171213; MA 47074 A 20171213; MX 2019007619 A 20171213; PE 2019001285 A 20171213; PH 12019501458 A 20190621; TW 106144527 A 20171219; US 201716472116 A 20171213; UY 37541 A 20171221